1,707 results · 40ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

SNN FLUORO NAVIGATION SYSTEM

FDA 510(k)
FDA Class 2 ·Neurology

CEDARA I-RESPONSE CEDARA PET/CT

FDA 510(k)
FDA Class 2 ·Radiology

CEDARA I-SOFTVIEW

FDA 510(k)
FDA Class 2 ·Radiology

ADVANCE MODEL UDS-ADV

FDA 510(k)
FDA Class 2 ·Gastroenterology, Urology

CART, MODE NUMBER UDS-CART

FDA 510(k)
FDA Class 2 ·Gastroenterology, Urology

VR NETSERVE

FDA 510(k)
FDA Class 1 ·Radiology

U-TEX

FDA 510(k)
FDA Class 1 ·Gastroenterology, Urology

GALAXY LITE

FDA 510(k)
FDA Class 1 ·Physical Medicine

SNN SYSTEM WITH OLIVIER DOUBLE CHUCK SUPPORT ARM OPTION

FDA 510(k)
FDA Class 2 ·Neurology

SNN SYSTEM INCLUDING THE TOMOGUIDE OPTION

FDA 510(k)
FDA Class 2 ·Neurology

CYSTOSCOPE, MODELS CE0004-C, CE006-C, CE3004-C, CE3027-C, CE7004-C, CE1204-C, CE1227-C

FDA 510(k)
FDA Class 2 ·Gastroenterology, Urology

CEDARA CARDIOLOGY VIEWER, CARDIOLOGY ARCHIVE VIEWER, CARDIOLOGY CD VIEWER

FDA 510(k)
FDA Class 2 ·Radiology

UORCAP,MODEL NUMBER UDS-UCAP

FDA 510(k)
FDA Class 2 ·Gastroenterology, Urology

SNN STEREOTAXIC PLANNING APPLICATION; SNN STEREOTACTIC APPLICATION

FDA 510(k)
FDA Class 2 ·Neurology

CAPELLA

FDA 510(k)
FDA Class 1 ·Physical Medicine

ID. STORE (RELEASE 2.0)

FDA 510(k)
FDA Class 1 ·Radiology

P2psa

FDA Pre-Market Approval
FDA Class 3 ·ACCESS HYBRITECH P2PSA REAGENTS ON THE ACCESS IMMUNOASSAY SYSTEMS

Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions

FDA Pre-Market Approval
FDA Class 3 ·ACCESS HYBRITECH FREE PSA REAGENTS ON THE ACCESS IMMUNOASSAY SYSTEMS

Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

FDA Pre-Market Approval
FDA Class 3 ·ACCESS HYBRITECH PSA REAGENTS ON THE IMMUNOASSAY SYSTEMS

Kit, Test, Alpha-Fetoprotein For Neural Tube Defects

FDA Pre-Market Approval
FDA Class 3 ·ACCESS AFP REAGENTS ON THE ACCESS IMMUNOASSAY SYSTEMS